Feasibility of repairing defects followed by treatment with pulmonary hypertension-specific drugs (repair and treat) in patients with pulmonary hypertension associated with atrial septal defect: Study protocol for interventional trial

Satoshi Akagi; Kazufumi Nakamura; Teiji Akagi; Koji Nakagawa; Yoichi Takaya; Toshihiro Sarashina; Kentaro Ejiri; Hiroshi Ito

Feasibility of repairing defects followed by treatment with pulmonary hypertension-specific drugs (repair and treat) in patients with pulmonary hypertension associated with atrial septal defect: Study protocol for interventional trial

Satoshi Akagi, Kazufumi Nakamura, Teiji Akagi, Koji Nakagawa, Yoichi Takaya, Toshihiro Sarashina, Kentaro Ejiri, Hiroshi Ito

Research output: Contribution to journal › Article › peer-review

2 Citations (Scopus)

Abstract

A treatment strategy for patients with pulmonary hypertension (PH) and atrial septal defect (ASD) remains unclear. This study was designed to evaluate the effects of initial repair of ASD followed by treatment with PH-specific drugs in patients with PH and ASD. Eligible patients receive transcatheter ASD closure followed by treatment with bosentan and sildenafil. Right heart catheterization is performed at baseline and at 12, 24 and 48 weeks. The primary endpoint is change in pulmonary artery pressure and pulmonary vascular resistance from baseline to follow-up. This study should provide valuable information to establish a therapeutic strategy for PH and ASD.

Original language	English
Pages (from-to)	397-400
Number of pages	4
Journal	Acta medica Okayama
Volume	70
Issue number	5
Publication status	Published - 2016

Keywords

Atrial septal defect
Pulmonary hypertension
Repair and treat
Transcatheter closure

ASJC Scopus subject areas

Biochemistry, Genetics and Molecular Biology(all)

Fingerprint

Dive into the research topics of 'Feasibility of repairing defects followed by treatment with pulmonary hypertension-specific drugs (repair and treat) in patients with pulmonary hypertension associated with atrial septal defect: Study protocol for interventional trial'. Together they form a unique fingerprint.

Cite this

Akagi, S., Nakamura, K., Akagi, T., Nakagawa, K., Takaya, Y., Sarashina, T., Ejiri, K., & Ito, H. (2016). Feasibility of repairing defects followed by treatment with pulmonary hypertension-specific drugs (repair and treat) in patients with pulmonary hypertension associated with atrial septal defect: Study protocol for interventional trial. Acta medica Okayama, 70(5), 397-400.

Feasibility of repairing defects followed by treatment with pulmonary hypertension-specific drugs (repair and treat) in patients with pulmonary hypertension associated with atrial septal defect : Study protocol for interventional trial. / Akagi, Satoshi ; Nakamura, Kazufumi ; Akagi, Teiji et al.

In: Acta medica Okayama, Vol. 70, No. 5, 2016, p. 397-400.

Research output: Contribution to journal › Article › peer-review

Akagi, S , Nakamura, K , Akagi, T , Nakagawa, K , Takaya, Y, Sarashina, T, Ejiri, K & Ito, H 2016, 'Feasibility of repairing defects followed by treatment with pulmonary hypertension-specific drugs (repair and treat) in patients with pulmonary hypertension associated with atrial septal defect: Study protocol for interventional trial', Acta medica Okayama, vol. 70, no. 5, pp. 397-400.

@article{0766e47e18d84f6b8c75fc73e236a516,

title = "Feasibility of repairing defects followed by treatment with pulmonary hypertension-specific drugs (repair and treat) in patients with pulmonary hypertension associated with atrial septal defect: Study protocol for interventional trial",

abstract = "A treatment strategy for patients with pulmonary hypertension (PH) and atrial septal defect (ASD) remains unclear. This study was designed to evaluate the effects of initial repair of ASD followed by treatment with PH-specific drugs in patients with PH and ASD. Eligible patients receive transcatheter ASD closure followed by treatment with bosentan and sildenafil. Right heart catheterization is performed at baseline and at 12, 24 and 48 weeks. The primary endpoint is change in pulmonary artery pressure and pulmonary vascular resistance from baseline to follow-up. This study should provide valuable information to establish a therapeutic strategy for PH and ASD.",

keywords = "Atrial septal defect, Pulmonary hypertension, Repair and treat, Transcatheter closure",

author = "Satoshi Akagi and Kazufumi Nakamura and Teiji Akagi and Koji Nakagawa and Yoichi Takaya and Toshihiro Sarashina and Kentaro Ejiri and Hiroshi Ito",

note = "Publisher Copyright: {\textcopyright} 2016 by Okayama University Medical School.",

year = "2016",

language = "English",

volume = "70",

pages = "397--400",

journal = "Acta Medica Okayama",

issn = "0386-300X",

publisher = "Okayama University",

number = "5",

}

TY - JOUR

T1 - Feasibility of repairing defects followed by treatment with pulmonary hypertension-specific drugs (repair and treat) in patients with pulmonary hypertension associated with atrial septal defect

T2 - Study protocol for interventional trial

AU - Akagi, Satoshi

AU - Nakamura, Kazufumi

AU - Akagi, Teiji

AU - Nakagawa, Koji

AU - Takaya, Yoichi

AU - Sarashina, Toshihiro

AU - Ejiri, Kentaro

AU - Ito, Hiroshi

PY - 2016

Y1 - 2016

N2 - A treatment strategy for patients with pulmonary hypertension (PH) and atrial septal defect (ASD) remains unclear. This study was designed to evaluate the effects of initial repair of ASD followed by treatment with PH-specific drugs in patients with PH and ASD. Eligible patients receive transcatheter ASD closure followed by treatment with bosentan and sildenafil. Right heart catheterization is performed at baseline and at 12, 24 and 48 weeks. The primary endpoint is change in pulmonary artery pressure and pulmonary vascular resistance from baseline to follow-up. This study should provide valuable information to establish a therapeutic strategy for PH and ASD.

AB - A treatment strategy for patients with pulmonary hypertension (PH) and atrial septal defect (ASD) remains unclear. This study was designed to evaluate the effects of initial repair of ASD followed by treatment with PH-specific drugs in patients with PH and ASD. Eligible patients receive transcatheter ASD closure followed by treatment with bosentan and sildenafil. Right heart catheterization is performed at baseline and at 12, 24 and 48 weeks. The primary endpoint is change in pulmonary artery pressure and pulmonary vascular resistance from baseline to follow-up. This study should provide valuable information to establish a therapeutic strategy for PH and ASD.

KW - Atrial septal defect

KW - Pulmonary hypertension

KW - Repair and treat

KW - Transcatheter closure

UR - http://www.scopus.com/inward/record.url?scp=84997815929&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84997815929&partnerID=8YFLogxK

M3 - Article

C2 - 27777434

AN - SCOPUS:84997815929

SN - 0386-300X

VL - 70

SP - 397

EP - 400

JO - Acta Medica Okayama

JF - Acta Medica Okayama

IS - 5

ER -

Feasibility of repairing defects followed by treatment with pulmonary hypertension-specific drugs (repair and treat) in patients with pulmonary hypertension associated with atrial septal defect: Study protocol for interventional trial

Abstract

Keywords

ASJC Scopus subject areas

Other files and links

Fingerprint

Cite this